Washington, D.C. 20515 Dear Congressman Schrader and Congressman Kinzinger: On behalf of the millions of patients, consumers, providers, communities of color, and taxpayers our organizations represent, we write to thank you for your leadership in introducing the BIOSIM Act (H.R. 2815). Biosimilar medicines hold enormous potential to lower the cost of prescription drugs but face significant barriers to adoption. Congressional action on innovative solutions, like the BIOSIM Act, is critical to reducing costs and improving patient access to biosimilars in the U.S. The Food and Drug Administration (FDA) has approved 29 biosimilar medicines since 2015.i Patients with cancer, chronic kidney disease, rheumatoid arthritis and other conditions are benefitting from access to biosimilars. According to a recent analysis, women, seniors, and low-income individuals are expected to benefit most from increased access to biosimilars as they are predominantly impacted by the conditions currently treated by higher cost biologics for which biosimilar competition can reduce costs.ii However, despite average cost savings of 30 percent, biosimilar adoption continues to trail expectations.iii